Novo Nordisk shares fall after deal with Trump to slash obesity drug prices
NegativeFinancial Markets

Novo Nordisk shares fall after deal with Trump to slash obesity drug prices
Novo Nordisk's shares have taken a hit following a recent agreement with former President Trump aimed at reducing the prices of obesity drugs. This move, while potentially beneficial for consumers, raises concerns about the company's profitability and market position. Investors are wary of how this price cut could impact Novo Nordisk's revenue in the long term, making it a significant development in the pharmaceutical industry.
— via World Pulse Now AI Editorial System







